Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease

European Journal of Neurology

Volumn 19, Issue 1, 2012, Pages 105-113

  Ray Chaudhuri, K ^a   Martinez Martin, P ^b   Rolfe, K A ^c   Cooper, J ^c   Rockett, C B ^d   Giorgi, L ^c   Ondo, W G ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Nocturnal symptoms; Non motor symptoms; Parkinson's disease; Parkinson's disease sleep scale; Ropinirole prolonged release

Indexed keywords

LEVODOPA; PLACEBO; ROPINIROLE;

AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIGHT SLEEP; NOCTURIA; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WAKEFULNESS;

AGED; ANTIPARKINSON AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; PARKINSON DISEASE; QUALITY OF LIFE; SLEEP DISORDERS;

EID: 84155172975     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03442.x     Document Type: Article

References (22)

1. Happe S, Ludemann P, Berger K. The association between disease severity and sleep-related problems in patients with Parkinson's disease. Neuropsychobiology 2002; 46: 90-96.
2. Mehta SH, Morgan JC, Sethi KD. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectrum 2008; 13: 6-11.
3. Rye DB. Modulation of normal and pathologic motoneuron activity during sleep: insights from the neurology clinic, Parkinson's disease, and comments on parkinsonian-related sleepiness. Sleep Med 2002; 3(Suppl): S43-S49.
4. Chaudhuri KR. The basis for day and night-time control of symptoms of Parkinson's disease. Eur J Neurol 2002; 9(Suppl. 3): 40-43.
5. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010; 25: 704-709.
6. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
7. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 629-635.
8. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009; 15(Suppl. 1): S9-S15.
9. Tompson D, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007; 29: 2654-2666.
10. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-1115.
11. Abe K, Hikita T, Sakoda S. Sleep disturbances in Japanese patients with Parkinson's disease-comparing with patients in the UK. J Neurol Sci 2005; 234: 73-78.
12. Dhawan V, Dhoat S, Williams AJ, et al. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J Neurol Sci 2006; 248: 158-162.
13. Martinez-Martin P, Salvador C, Menendez-Guisasola L, et al. Parkinson's disease sleep scale: validation study of a Spanish version. Mov Disord 2004; 19: 1226-1232.
14. Tse W, Liu Y, Barthlen GM, et al. Clinical usefulness of the Parkinson's disease sleep scale. Parkinsonism Relat Disord 2005; 11: 317-321.
15. Margis R, Donis K, Schonwald SV, et al. Psychometric properties of the Parkinson's disease sleep scale - Brazilian version. Parkinsonism Relat Disord 2009; 15: 495-499.
16. Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008; 31: 261-266.
17. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245(Suppl. 1): S10-S14.
18. van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bull Inst Int Stat 1960; 37: 351-361.
19. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999; 14: 117-121.
20. Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson's disease. Postgrad Med J 2005; 81: 644-646.
21. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90-99.
22. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, the Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883-2895.